Ascelia Pharma AB (publ) (ticker: ACE), today presented updates on expected mid-2023 SPARKLE Phase 3 readout, as well as the launch strategy to address the 800 million USD global market opportunity with 100,000 procedures in the target patient population in the US alone. Investors, analysts, and media are invited to join today’s Investor Update with a live Q&A webcast at 14:00 CET.
The event consists of recorded presentations from Ascelia Pharma executives and a live Q&A webcast. The livestreamed Q&A webcast will take place today, Tuesday, March 14 from 14:00 CET.
“We have three key objectives for Ascelia Pharma in 2023. We met the first one by completing patient enrollment in SPARKLE in February. Headline result with the primary endpoint will be available in the middle of this year and together with our launch preparations those are our key activities to successfully pursue our mission to improve the life of people living with cancer by offering better treatment options.” said Magnus Corfitzen, CEO of Ascelia Pharma.
“The addressable market for Orviglance has a global value of 800 million dollars annually. This includes our previous estimate for the US, Europe, and Japan, as well as other relevant markets. Our update today also provides further details on pricing benchmarks and volume estimates; with 100,000 abdominal imaging procedures annually in our target patient population in the US alone”, says Julie Waras Brogren, Deputy CEO and CCO of Ascelia Pharma.
The Investor Update presentations include:
- Momentum for growth – Magnus Corfitzen, CEO
- Completing clinical development – Jennie Wilborgsson, VP Clinical Development & Andreas Norlin, CSO
- Attractive commercial opportunity – Julie Brogren, Deputy CEO & CCO
The presentations are now available on Ascelia Pharma’s website www.ascelia.com
A recording of the Q&A webcast will be published on Ascelia Pharma’s website after the event. All presentations will be held in English.